Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center
Table 3
Surgical and pathological results.
Items
Neoadjuvant group ()
Adjuvant group ()
value*
Margins: (%)
R0
19 (82.6)
28 (80.0)
0.807
R1/2
4 (17.4)
7 (20.0)
Postoperative complication: (%)
Anastomotic leak
1 (4.3)
0 (0)
0.507
Respiratory infection
2 (8.7)
3 (8.6)
Postoperative hemorrhage
1 (4.3)
1 (2.9)
Postoperative bowel obstruction
0 (0)
2 (5.7)
Pathological staging
T-stage: (%)
T1
1 (4.3)
2 (5.7)
0.335
T2
5 (21.7)
2 (5.7)
T3
4 (21.7)
8 (22.9)
T4
13 (52.1)
23 (65.7)
N-stage: (%)
N0
8 (34.8)
2 (5.7)
0.034
N1
3 (13.0)
9 (25.7)
N2
4 (17.4)
10 (28.6)
N3
8 (34.8)
14 (40.0)
Number of nodes harvested:
16 (0–49)
13 (3–40)
0.886
Number of metastatic lymph nodes:
3 (0–14)
6 (0–27)
0.040
Comparisons for categorical variables performed using chi-square test. values for number of nodes harvested and metastatic lymph nodes were calculated by Wilcoxon test.
